Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | QPCT | Q16769 | 3/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | ABL1 | P00519 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | HCK | P08631 | 2/20 | 0.32 |
| ▸ | SRC | P12931 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.32 |
| ▸ | MTOR | P42345 | 2/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.32 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.32 |
| ▸ | PRKDC | P78527 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL260041 | 0.81 | CLK4 (0.38) | PIK3C3QPCTGRM5CDC7PDE4A | |
| SCHEMBL18946168 | 0.78 | GRM5 (0.39) | PIK3C3QPCTGRM5DYRK1AKEAP1 | |
| SCHEMBL25251508 | 0.75 | OGA (0.39) | PIK3C3QPCTGRM5DYRK1AKEAP1 | |
| SCHEMBL18946166 | 0.74 | OGA (0.39) | PIK3C3QPCTGRM5DYRK1AKEAP1 | |
| SCHEMBL27046657 | 0.74 | GRM5 (0.36) | PIK3C3QPCTGRM5OGA | |
| SCHEMBL14144231 | 0.74 | PIK3C3 (0.38) | PIK3C3QPCTDYRK1AKEAP1OGA | |
| SCHEMBL2714523 | 0.73 | DYRK1A (0.49) | HDAC8DYRK1AKEAP1PIK3CGMEN1 | |
| SCHEMBL25214809 | 0.72 | MAPK1 (0.33) | HDAC8 | |
| SCHEMBL3186168 | 0.72 | OGA (0.35) | PIK3C3QPCTGRM5DYRK1AOGA | |
| SCHEMBL18554370 | 0.69 | OGA (0.39) | PIK3C3QPCTDYRK1AKEAP1OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600719-B2 | Salt inducible kinase inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4660192-A1 | SALT INDUCIBLE KINASE INHIBITORS | The General Hospital Corporation (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2024-01-25 | — | — | US | disclosed |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2024-01-25 | — | — | US | disclosed |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2024-01-25 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| EP-4192459-A1 | SALT INDUCIBLE KINASE INHIBITORS | The General Hospital Corporation (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-116234549-A | Salt-induced kinase inhibitors | 总医院公司 | 2023-06-06 | — | — | CN | disclosed |
| WO-2022031928-A1 | SALT INDUCIBLE KINASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2017093544-A1 | ALKYNYL PHOSPHINE GOLD COMPLEXES FOR TREATING BACTERIAL INFECTIONS | AUSPHERIX LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
| EP-1904494-B1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | LILLY CO ELI (US) | 2010-12-01 | — | — | EP | disclosed |
| US-7666879-B2 | Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY | 2009-09-10 | — | — | US | disclosed |
| EP-1904494-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006091671-A1 | IMIDAZO (1, 2-A) PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600719-B2 | Salt inducible kinase inhibitors | GRK6, SGK1, CSNK1A1 | PIK3C3 661/4885HDAC8 435/4885QPCT 4686/4885 |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC6, HDAC1, HDAC3 | PIK3C3 2633/4885HDAC8 9/4885QPCT 2799/4885 |
| US-20240025892-A1 | SALT INDUCIBLE KINASE INHIBITORS | SGK1, SGK2, SIK1 | PIK3C3 604/4885HDAC8 356/4885QPCT 4543/4885 |
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | KDR, FLT1, FLT4 | PIK3C3 1023/4885HDAC8 2306/4885QPCT 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.